Canada's Canopy Growth Q4 revenue rises

Canopy Growth

15/06/2026 12:18

Overview
Canada cannabis producer's Q4 revenue rose 8.6% yr/yr
Adjusted EBITDA loss for Q4 FY2026 narrowed yr/yr to C$6.3 mln

Outlook
Canopy Growth expects net revenue growth across the business in FY2027
Company projects meaningful improvements in gross margin from strengthened cultivation practices
Canopy Growth expects to achieve positive adjusted EBITDA during FY2027

Result Drivers
CANADA MEDICAL GROWTH - Q4 Canada medical cannabis revenue rose 27% yr/yr, driven by more insured patients and expanded product assortment
INTERNATIONAL REBOUND - Q4 international cannabis revenue rose 68% yr/yr as co addressed earlier supply chain challenges in Europe
DEVICE SALES DECLINE - Storz & Bickel revenue fell 14% yr/yr in Q4 due to lapping strong prior-year sales and continued consumer economic uncertainty

Company press release: ID:nBw85P8fka

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
 
C$84.69 mln
 
Q4 Adjusted EBITDA
 
-C$6.30 mln
 
Q4 Gross Margin
 
12%

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)